Topotecan for the treatment of relapsed small-cell lung cancer
National Institute for Health and Clinical Excellence
Record ID 32011000082
English
Authors' recommendations:
Oral topotecan is recommended as an option only for people with relapsed small-cell lung cancer for whom:• re-treatment with the first-line regimen is not considered appropriate and• the combination of cyclophosphamide, doxorubicin and vincristine (CAV) is contraindicated (for details of the contraindications to CAV see the summary of product characteristics for each of the component drugs).Intravenous topotecan is not recommended for people with relapsed small-cell lung cancer.People with relapsed small-cell lung cancer currently receiving oral topotecan who do not meet the criteria specified above, or who are receiving intravenous topotecan should have the option to continue their treatment until they and their clinicians consider it appropriate to stop.
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/nicemedia/live/12348/46326/46326.pdf
Year Published:
2009
URL for published report:
http://www.nice.org.uk/TA184
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England
MeSH Terms
- Humans
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Topotecan
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.